Base de dados : MEDLINE
Pesquisa : G08.852.880 [Categoria DeCS]
Referências encontradas : 8715 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 872 ir para página                         

  1 / 8715 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29351556
[Au] Autor:Li J; Tian Y; Guo S; Gu H; Yuan Q; Xie X
[Ad] Endereço:Chinese Academy of Sciences Key Laboratory of Receptor Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
[Ti] Título:Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms.
[So] Source:PLoS One;13(1):e0191469, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Benign prostatic hyperplasia (BPH) is an age-related disease, affecting a majority of elderly men worldwide. Medical management of BPH is an alternative to surgical treatment of this disease. Currently, α1-adrenergic receptor (α1-AR) antagonists are among the first line drugs to treat BPH by reducing the tension of urinary track and thus the obstructive symptoms in voiding. In drug development, old male dogs with spontaneous BPH are considered the golden standard of the animal models. However, old dogs (>6 years) are expensive and not all old dogs develop BPH. So it is necessary to develop more accessible animal models for drug efficacy evaluation. Here we describe the development of testosterone-induced BPH models in both rats and young adult dogs and their applications in the in vivo evaluation of α1-AR antagonist. The BPH rats and dogs induced by chronic testosterone treatment have significantly increased micturition frequency and reduced mean voided volume, very similar to the clinical symptoms of BPH patients. Silodosin, an α1-AR antagonist, significantly reduces the urinary frequency and increases the voided volume in BPH model animals in a dose-dependent manner. The results demonstrate that testosterone-induced BPH rat and dog models might provide a more efficient way to evaluate micturition behavior in anti-BPH drug studies.
[Mh] Termos MeSH primário: Sintomas do Trato Urinário Inferior/tratamento farmacológico
Hiperplasia Prostática/induzido quimicamente
Testosterona/toxicidade
[Mh] Termos MeSH secundário: Antagonistas de Receptores Adrenérgicos alfa 1/uso terapêutico
Idoso
Animais
Modelos Animais de Doenças
Cães
Avaliação Pré-Clínica de Medicamentos
Feminino
Seres Humanos
Indóis/uso terapêutico
Sintomas do Trato Urinário Inferior/etiologia
Sintomas do Trato Urinário Inferior/fisiopatologia
Masculino
Hiperplasia Prostática/complicações
Hiperplasia Prostática/patologia
Ratos
Ratos Sprague-Dawley
Testosterona/administração & dosagem
Micção/efeitos dos fármacos
Agentes Urológicos/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adrenergic alpha-1 Receptor Antagonists); 0 (Indoles); 0 (Urological Agents); 3XMK78S47O (Testosterone); CUZ39LUY82 (silodosin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180120
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191469


  2 / 8715 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:29385990
[Au] Autor:Schoendorfer N; Sharp N; Seipel T; Schauss AG; Ahuja KDK
[Ad] Endereço:School of Medicine, University of Queensland, Herston, Australia.
[Ti] Título:Urox containing concentrated extracts of Crataeva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root, in the treatment of symptoms of overactive bladder and urinary incontinence: a phase 2, randomised, double-blind placebo controlled trial.
[So] Source:BMC Complement Altern Med;18(1):42, 2018 Jan 31.
[Is] ISSN:1472-6882
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Storage lower urinary tract symptoms (LUTS) including overactive bladder (OAB) and urinary incontinence (UI) affect millions of people worldwide, significantly impacting quality of life. Plant based medicines have been documented both empirically and in emerging scientific research to have varying benefits in reducing bladder symptoms. We assessed the efficacy of Urox®, a proprietary combination of phytomedicine extracts including, Cratevox™ (Crataeva nurvala) stem bark, Equisetem arvense stem and Lindera aggregata root, in reducing symptoms of OAB and UI. METHODS: Efficacy of the herbal combination on a variety of bladder symptoms compared to an identical placebo, were documented in a randomised, double-blind, placebo controlled trial conducted at two primary care centres. Data were collected at baseline, 2, 4 and 8 weeks, with the primary outcome being self-reported urinary frequency. Statistical analysis included mixed effects ordered logistic regression with post hoc Holm's test to account for repeated measures, and included an intention-to-treat analysis. RESULTS: One hundred and fifty participants (59% female, aged; mean ± SD; 63.5 ± 13.1 years) took part in the study. At week 8, urinary day frequency was significantly lower (OR 0.01; 95%CI 0.01 to 0.02; p < 0.001) in response to treatment (mean ± SD; 7.69 ± 2.15/day) compared to placebo (10.95 ± 2.47/day). Similarly, episodes of nocturia were significantly fewer (OR 0.03; 95%CI 0.02 to 0.05) after 8 weeks of treatment (2.16 ± 1.49/night) versus placebo (3.14 ± 1.36/night). Symptoms of urgency (OR 0.02; 95%CI 0.01 to 0.03), and total incontinence (OR 0.03; 95% CI 0.01 to 0.06) were also lower (all p < 0.01) in the treatment group. Significant improvements in quality of life were reported after treatment in comparison to placebo. No significant side effects were observed resulting in withdrawal from treatment. CONCLUSIONS: The outcome of this study demonstrated both statistical significance and clinical relevance in reducing symptoms of OAB, urinary frequency and/or urgency and incontinence. The demonstrated viability of the herbal combination to serve as an effective treatment, with minimal side-effects, warrants further longer term research and consideration by clinicians. TRIAL REGISTRATION: NCT02396160 (registered on 17 March 2015 - before any statistical analyses commenced).
[Mh] Termos MeSH primário: Extratos Vegetais/uso terapêutico
Bexiga Urinária Hiperativa/tratamento farmacológico
Incontinência Urinária/tratamento farmacológico
Agentes Urológicos/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Capparaceae
Equisetum
Feminino
Seres Humanos
Lindera
Masculino
Registros Médicos
Meia-Idade
Fitoterapia
Extratos Vegetais/farmacologia
Micção/efeitos dos fármacos
Agentes Urológicos/farmacologia
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Plant Extracts); 0 (Urological Agents)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180202
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1186/s12906-018-2101-4


  3 / 8715 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465566
[Au] Autor:Zhao Y; Zhou J; Mo Q; Wang Y; Yu J; Liu Z
[Ad] Endereço:Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical Sciences.
[Ti] Título:Acupuncture for adults with overactive bladder: A systematic review and meta-analysis of randomized controlled trials.
[So] Source:Medicine (Baltimore);97(8):e9838, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Overactive bladder is stated as the occurrence of urinary urgency which will cause negative impacts and decrease patients' health-related quality of life. The aim of this systematic review is to assess the efficiency and safety of acupuncture for adults with overactive bladder (OAB) comparing with sham-acupuncture, drugs, and acupuncture plus drugs. METHODS: We independently searched 9 databases from beginning to August 15, 2017. Two writers extracted data at the same time independently. Study outcomes were calculated by standardized mean differences (SMD) with 95% confidence intervals (CIs) and mean difference (MD) with 95% CIs. RESULTS: Ten randomized controlled trials (RCTs) with 794 patients were included in this systematic review. The combined results showed that electroacupuncture (EA) may be more effective than sham electroacupuncture (sham EA) in improving the 24-hour nocturia episodes and EA may enhance tolterodine for relieving voiding symptoms and enhancing patients' quality of life. However, more trials with high quality and larger sample sizes will be needed in the future to provide sufficient evidence. Only 15 of 794 OAB patients from the included studies reported mild adverse reactions related to EA, therefore, acupuncture is safe for treating OAB. CONCLUSION: Acupuncture might have effect in decreasing the number of micturition episodes, incontinence episodes, and nocturia episodes. However, the evidence is insufficient to show the effect using acupuncture alone or the additional effect to drugs in treating OAB.
[Mh] Termos MeSH primário: Terapia por Acupuntura
Bexiga Urinária Hiperativa/terapia
[Mh] Termos MeSH secundário: Terapia por Acupuntura/efeitos adversos
Adulto
Seres Humanos
Bexiga Urinária Hiperativa/tratamento farmacológico
Bexiga Urinária Hiperativa/fisiopatologia
Micção
Agentes Urológicos/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Urological Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009838


  4 / 8715 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29190218
[Au] Autor:Chang AJ; Nomura Y; Barodka VM; Hori D; Magruder JT; Katz NM; Berkowitz DE; Hogue CW
[Ad] Endereço:From the *Center for Bioengineering Innovation and Design, Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland; †Division of Cardiac Surgery, Department of Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland; ‡Department of Anesthesiology and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland; and §Department of Anesthesiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
[Ti] Título:Validation of a Real-Time Minute-to-Minute Urine Output Monitor and the Feasibility of Its Clinical Use for Patients Undergoing Cardiac Surgery.
[So] Source:Anesth Analg;125(6):1883-1886, 2017 12.
[Is] ISSN:1526-7598
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Acute kidney injury after cardiac surgery is associated with increased morbidity and mortality. Methods for measuring urine output in real time may better ensure renal perfusion perioperatively in contrast to the current standard of care where urine output is visually estimated after empiric epochs of time. In this study, we describe an accurate method for monitoring urine output continuously during cardiopulmonary bypass. This may provide a means for setting patient-specific targets for blood pressure and cardiopulmonary bypass flow as a potential strategy to reduce the risk for acute kidney injury.
[Mh] Termos MeSH primário: Lesão Renal Aguda/urina
Procedimentos Cirúrgicos Cardíacos/normas
Sistemas de Computação/normas
Monitorização Fisiológica/normas
Complicações Pós-Operatórias/urina
Micção/fisiologia
[Mh] Termos MeSH secundário: Lesão Renal Aguda/diagnóstico
Lesão Renal Aguda/etiologia
Idoso
Procedimentos Cirúrgicos Cardíacos/efeitos adversos
Procedimentos Cirúrgicos Cardíacos/tendências
Sistemas de Computação/tendências
Estudos de Viabilidade
Feminino
Seres Humanos
Masculino
Meia-Idade
Monitorização Fisiológica/tendências
Complicações Pós-Operatórias/diagnóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE
[do] DOI:10.1213/ANE.0000000000002217


  5 / 8715 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29197314
[Au] Autor:Meekins AR; Siddiqui NY; Amundsen CL; Kuchibhatla M; Dieter AA
[Ad] Endereço:From the Departments of Obstetrics and Gynecology and Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina, and the Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill.
[Ti] Título:Improving Postoperative Efficiency: An Algorithm for Expedited Void Trials After Urogynecologic Surgery.
[So] Source:South Med J;110(12):785-790, 2017 Dec.
[Is] ISSN:1541-8243
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To evaluate the relation between voided volume and void trial "success" to create an algorithm that minimizes the need for postvoid residual volume (PVR) assessment in backfill-assisted void trials. METHODS: This article is an ancillary analysis of deidentified data from a randomized trial evaluating prophylactic antibiotics after urogynecologic surgery. Void trials were routinely performed after surgery; voided volumes, PVR, and void trial outcomes were collected. The void trial regimen was as follows: the bladder was backfilled with 300 mL of normal saline or until the patient reported the urgency to void, the catheter was removed, and the participant was prompted to void immediately. PVR volume was measured either by sonographic bladder scan or catheterization. Voided volumes were categorized in 25-mL increments from 50 to 225 mL. For each voided volume range, the PVR and void trial outcome data were incorporated to calculate sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) in terms of ability of voided volume alone to predict a passing void trial result. An algorithm was created using the voided volumes that optimize PPV and NPV. RESULTS: The study population included 255 participants. Voided volumes <100 mL and ≥200 mL were identified as optimal thresholds to predict failure and passage of backfill-assisted void trials, respectively. When patients voided <100 mL, 3% passed their void trial (NPV odds ratio 96.7, 95% confidence interval 88.6-99.5). When patients voided ≥200 mL, 97% passed (PPV odds ratio 97.4, 95% confidence interval 93.5-99.3). CONCLUSIONS: We propose an algorithm for void trials after urogynecologic surgery. After backfilling the bladder if voided volume is ≥200 mL, the void trial is successful and no PVR is needed; if voided volume is between 100 and 199 mL, the void trial is indeterminate and PVR is recommended; and if voided volume is <100 mL, the void trial is unsuccessful and catheterization is needed. Applying this algorithm to our study population would have eliminated the need for PVR in 85% of patients. Calculated PPVs and NPVs depend on the prevalence of voiding dysfunction in the population being studied, and therefore may be unique to our institution.
[Mh] Termos MeSH primário: Procedimentos Cirúrgicos em Ginecologia/efeitos adversos
Pelve/cirurgia
Cuidados Pós-Operatórios/métodos
Complicações Pós-Operatórias/diagnóstico
Transtornos Urinários/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Idoso
Algoritmos
Feminino
Seres Humanos
Meia-Idade
Complicações Pós-Operatórias/etiologia
Valor Preditivo dos Testes
Estudos Retrospectivos
Sensibilidade e Especificidade
Fatores de Tempo
Bexiga Urinária/fisiopatologia
Micção/fisiologia
Transtornos Urinários/etiologia
Urodinâmica
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171220
[Lr] Data última revisão:
171220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171203
[St] Status:MEDLINE
[do] DOI:10.14423/SMJ.0000000000000733


  6 / 8715 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28953969
[Au] Autor:Shin DH; Lee YK; Oh J; Yoon JW; Rhee SY; Kim EJ; Ryu J; Cho A; Jeon HJ; Choi MJ; Noh JW
[Ad] Endereço:Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.
[Ti] Título:Vascular calcification and cardiac function according to residual renal function in patients on hemodialysis with urination.
[So] Source:PLoS One;12(9):e0185296, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Vascular calcification is common and may affect cardiac function in patients with end-stage renal disease (ESRD). However, little is known about the effect of residual renal function on vascular calcification and cardiac function in patients on hemodialysis. METHODS: This study was conducted between January 2014 and January 2017. One hundred six patients with residual renal function on maintenance hemodialysis for 3 months were recruited. We used residual renal urea clearance (KRU) to measure residual renal function. First, abdominal aortic calcification score (AACS) and brachial-ankle pulse wave velocity (baPWV) were measured in patients on hemodialysis. Second, we performed echocardiography and investigated new cardiovascular events after study enrollment. RESULTS: The median KRU was 0.9 (0.3-2.5) mL/min/1.73m2. AACS (4.0 [1.0-10.0] vs. 3.0 [0.0-8.0], p = 0.05) and baPWV (1836.1 ± 250.4 vs. 1676.8 ± 311.0 cm/s, p = 0.01) were significantly higher in patients with a KRU < 0.9 mL/min/1.73m2 than a KRU ≥ 0.9 mL/min/1.73m2. Log-KRU significantly negatively correlated with log-AACS (ß = -0.29, p = 0.002) and baPWV (ß = -0.19, P = 0.05) after factor adjustment. The proportion of left ventricular diastolic dysfunction was significantly higher in patients with a KRU < 0.9 mL/min/1.73m2 than with a KRU ≥ 0.9 mL/min/1.73m2 (67.9% vs. 49.1%, p = 0.05). Patients with a KRU < 0.9 mL/min/1.73m2 showed a higher tendency of cumulative cardiovascular events compared to those with a KRU ≥ 0.9 ml/min/1.73m2 (P = 0.08). CONCLUSIONS: Residual renal function was significantly associated with vascular calcification and left ventricular diastolic dysfunction in patients on hemodialysis.
[Mh] Termos MeSH primário: Testes de Função Cardíaca
Testes de Função Renal
Rim/fisiopatologia
Diálise Renal
Micção/fisiologia
Calcificação Vascular/fisiopatologia
[Mh] Termos MeSH secundário: Índice Tornozelo-Braço
Aorta Abdominal/patologia
Aorta Abdominal/fisiopatologia
Demografia
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Masculino
Meia-Idade
Análise de Onda de Pulso
Ureia/metabolismo
Calcificação Vascular/diagnóstico por imagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
8W8T17847W (Urea)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0185296


  7 / 8715 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28902866
[Au] Autor:Park J; Cho SY; Cho MC; Jeong H; Son H
[Ad] Endereço:Department of Urology, Seoul National University College of Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea.
[Ti] Título:5-year long-term efficacy of 120-W GreenLight photoselective vaporization of the prostate for benign prostate hyperplasia.
[So] Source:PLoS One;12(9):e0184442, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To investigate 5-year long-term postoperative efficacy in benign prostate hyperplasia (BPH) following 120-W GreenLight high-performance system photoselective vaporization of the prostate (HPS-PVP). METHODS: This was a retrospective study of surgical outcomes in 159 men who underwent HPS-PVP and were followed over 60 months postoperatively. Definitions of treatment success were established based on the following three variables: international prostate symptom scores (IPSS), maximum flow rates (Qmax), and quality of life scores QoL). Logistic regression analyses were performed to determine predictors of the postoperative success. RESULTS: Postoperative IPSS/QoL, Qmax and post-voided residual urine volume were significantly improved after HPS-PVP. Postoperative Prostate specific antigen and prostate volume were also well reduced and sustained for 5 years. The postoperative success rate was assessed as 82.1%, 80.8% and 76.1% for each 1-, 3-, and 5-year. Thirty-eight (23.9%) patients had immediate postoperative complications, which were managed successfully with nonsurgical methods. None required transfusions, two (1.2%) patients required endoscopic reoperation for postoperative voiding difficulty due to bladder neck contracture or urethral stricture, and five (3.1%) required HPS-PVP reoperation. Presence of diabetes, voiding symptom subscore, QoL, maximal cystometric capacity, and bladder outlet obstructive index were valuable preoperative parameters for predicting postoperative success. CONCLUSIONS: HPS-PVP is an effective, long-term treatment option for BPH, with sustained efficacy of 76.1% at 5-year follow up. Several preoperative parameters could help to predict the durable surgical improvements.
[Mh] Termos MeSH primário: Terapia a Laser/métodos
Hiperplasia Prostática/cirurgia
[Mh] Termos MeSH secundário: Idoso
Seres Humanos
Masculino
Meia-Idade
Tamanho do Órgão
Complicações Pós-Operatórias/epidemiologia
Complicações Pós-Operatórias/etiologia
Período Pós-Operatório
Próstata/patologia
Próstata/cirurgia
Antígeno Prostático Específico/sangue
Hiperplasia Prostática/sangue
Hiperplasia Prostática/patologia
Qualidade de Vida
Estudos Retrospectivos
Ressecção Transuretral da Próstata/métodos
Resultado do Tratamento
Micção/fisiologia
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
EC 3.4.21.77 (Prostate-Specific Antigen)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170914
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0184442


  8 / 8715 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28845952
[Au] Autor:Korneev IA
[Ad] Endereço:Department of Urology, First Pavlov State Medical University of St. Peterburg of Minzdrav of Russia, St. Petersburg, Russia.
[Ti] Título:[Russian experience with Vitaprost Forte suppositories in patients with lower urinary tract symptoms and benign prostatic hyperplasia: comparative analysis of studies].
[So] Source:Urologiia;(3):138-144, 2017 Jul.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The article reviews the domestic studies showing the efficacy and safety of suppositories containing prostate extract (Samprost substance) Vitaprost Forte in treating men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. The data obtained by Russian specialists confirm the effectiveness of Vitaprost Forte suppositories in managing patients with moderate LUTS and infravesical obstruction caused by BPH to reduce dysuria, improve the quality of life and normalize urodynamic parameters.
[Mh] Termos MeSH primário: Sintomas do Trato Urinário Inferior/tratamento farmacológico
Peptídeos/uso terapêutico
Hiperplasia Prostática/tratamento farmacológico
[Mh] Termos MeSH secundário: Avaliação Pré-Clínica de Medicamentos
Seres Humanos
Masculino
Peptídeos/administração & dosagem
Peptídeos/farmacologia
Supositórios
Resultado do Tratamento
Micção/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Peptides); 0 (Suppositories); 0 (Vitaprost)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170829
[St] Status:MEDLINE


  9 / 8715 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28637788
[Au] Autor:Gonzalez EJ; Grill WM
[Ad] Endereço:Department of Biomedical Engineering, Duke University, Durham, North Carolina.
[Ti] Título:The effects of neuromodulation in a novel obese-prone rat model of detrusor underactivity.
[So] Source:Am J Physiol Renal Physiol;313(3):F815-F825, 2017 Sep 01.
[Is] ISSN:1522-1466
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Obesity is a global epidemic associated with an increased risk for lower urinary tract dysfunction. Inefficient voiding and urinary retention may arise in late-stage obesity when the expulsive force of the detrusor smooth muscle cannot overcome outlet resistance. Detrusor underactivity (DUA) and impaired contractility may contribute to the pathogenesis of nonobstructive urinary retention. We used cystometry and electrical stimulation of peripheral nerves (pudendal and pelvic nerves) to characterize and improve bladder function in urethane-anesthetized obese-prone (OP) and obese-resistant (OR) rats following diet-induced obesity (DIO). OP rats exhibited urinary retention and impaired detrusor contractility following DIO, reflected as increased volume threshold, decreased peak micturition pressure, and decreased voiding efficiency (VE) compared with OR rats. Electrical stimulation of the sensory branch of the pudendal nerve did not increase VE, whereas patterned bursting stimulation of the motor branch of the pudendal nerve increased VE twofold in OP rats. OP rats required increased amplitude of electrical stimulation of the pelvic nerve to elicit bladder contractions, and maximum evoked bladder contraction amplitudes were decreased relative to OR rats. Collectively, these studies characterize a novel animal model of DUA that can be used to determine pathophysiology and suggest that neuromodulation is a potential management option for DUA.
[Mh] Termos MeSH primário: Terapia por Estimulação Elétrica/métodos
Plexo Hipogástrico/fisiopatologia
Músculo Liso/inervação
Obesidade/complicações
Nervo Pudendo/fisiopatologia
Bexiga Urinária/inervação
Retenção Urinária/terapia
Micção
[Mh] Termos MeSH secundário: Animais
Dieta Hiperlipídica
Modelos Animais de Doenças
Feminino
Contração Muscular
Retenção Urinária/etiologia
Retenção Urinária/fisiopatologia
Urodinâmica
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171028
[Lr] Data última revisão:
171028
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170623
[St] Status:MEDLINE
[do] DOI:10.1152/ajprenal.00242.2017


  10 / 8715 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28637786
[Au] Autor:Kadekawa K; Majima T; Shimizu T; Wada N; de Groat WC; Kanai AJ; Goto M; Yoshiyama M; Sugaya K; Yoshimura N
[Ad] Endereço:Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
[Ti] Título:The role of capsaicin-sensitive C-fiber afferent pathways in the control of micturition in spinal-intact and spinal cord-injured mice.
[So] Source:Am J Physiol Renal Physiol;313(3):F796-F804, 2017 Sep 01.
[Is] ISSN:1522-1466
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We examined bladder and urethral sphincter activity in mice with or without spinal cord injury (SCI) after C-fiber afferent desensitization induced by capsaicin pretreatment and changes in electrophysiological properties of mouse bladder afferent neurons 4 wk after SCI. Female C57BL/6N mice were divided into four groups: ) spinal intact (SI)-control, ) SI-capsaicin pretreatment (Cap), ) SCI-control, and ) SCI-Cap groups. Continuous cystometry and external urethral sphincter (EUS)-electromyogram (EMG) were conducted under an awake condition. In the Cap groups, capsaicin (25, 50, or 100 mg/kg) was injected subcutaneously 4 days before the experiments. In the SI-Cap group, 100 mg/kg capsaicin pretreatment significantly increased bladder capacity and decreased the silent period duration of EUS/EMG compared with the SI-control group. In the SCI-Cap group, 50 and 100 mg/kg capsaicin pretreatment decreased the number of nonvoiding contractions (NVCs) and the duration of reduced EUS activity during voiding, respectively, compared with the SCI-control group. In SCI mice, hexamethonium, a ganglionic blocker, almost completely blocked NVCs, suggesting that they are of neurogenic origin. Patch-clamp recordings in capsaicin-sensitive bladder afferent neurons from SCI mice showed hyperexcitability, which was evidenced by decreased spike thresholds and increased firing rate compared with SI mice. These results indicate that capsaicin-sensitive C-fiber afferent pathways, which become hyperexcitable after SCI, can modulate bladder and urethral sphincter activity in awake SI and SCI mice. Detrusor overactivity as shown by NVCs in SCI mice is significantly but partially dependent on capsaicin-sensitive C-fiber afferents, whereas the EUS relaxation during voiding is enhanced by capsaicin-sensitive C-fiber bladder afferents in SI and SCI mice.
[Mh] Termos MeSH primário: Capsaicina/farmacologia
Fibras Nervosas Amielínicas/efeitos dos fármacos
Neurônios Aferentes/efeitos dos fármacos
Fármacos do Sistema Sensorial/farmacologia
Traumatismos da Medula Espinal/tratamento farmacológico
Uretra/inervação
Bexiga Urinária Hiperativa/prevenção & controle
Bexiga Urinária/inervação
Micção/efeitos dos fármacos
[Mh] Termos MeSH secundário: Potenciais de Ação
Animais
Modelos Animais de Doenças
Eletromiografia
Feminino
Bloqueadores Ganglionares/farmacologia
Camundongos Endogâmicos C57BL
Fibras Nervosas Amielínicas/metabolismo
Neurônios Aferentes/metabolismo
Técnicas de Patch-Clamp
Pressão
Traumatismos da Medula Espinal/complicações
Traumatismos da Medula Espinal/fisiopatologia
Fatores de Tempo
Bexiga Urinária Hiperativa/etiologia
Bexiga Urinária Hiperativa/fisiopatologia
Urodinâmica/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Ganglionic Blockers); 0 (Sensory System Agents); S07O44R1ZM (Capsaicin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171005
[Lr] Data última revisão:
171005
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170623
[St] Status:MEDLINE
[do] DOI:10.1152/ajprenal.00097.2017



página 1 de 872 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde